Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, May 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 147 articles:
HTML format


 

Single Articles

  1. LI G, Niu HM, Wu HT, Lei BY, et al
    Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis.
    Clin Invest Med. 2017;40:E81-E94.
    Abstract    

    Abstract available


  2. Nod for Atezolizumab in Advanced Bladder Cancer.
    Cancer Discov. 2017 Apr 26. doi: 10.1158/2159-8290.CD-NB2017.
    Abstract    

    Abstract available

  3. CORMIO L, Sanguedolce F, Cormio A, Massenio P, et al
    Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer.
    Oncotarget. 2017;8:25433-25441.
    Abstract    

    Abstract available

  4. LIN J, Zhan Y, Liu Y, Chen Z, et al
    Increased expression of ZEB1-AS1 correlates with higher histopathological grade and promotes tumorigenesis in bladder cancer.
    Oncotarget. 2017;8:24202-24212.
    Abstract    

    Abstract available

  5. ZHU XX, Yan YW, Ai CZ, Jiang S, et al
    Jarid2 is essential for the maintenance of tumor initiating cells in bladder cancer.
    Oncotarget. 2017;8:24483-24490.
    Abstract    

    Abstract available

  6. KIM TS, Chung JI, Noh GH, Hwang H, et al
    Toward Better Predictions of Chemosensitivity: Comparative Study of Conventional and Simulated Chemosensitivity Tests for Bladder Cancer Cell Lines.
    Ann Lab Med. 2017;37:343-345.
    Abstract    



  7. ZHANG YX, Qin CP, Zhang XQ, Wang QR, et al
    Knocking down glycoprotein nonmetastatic melanoma protein B suppresses the proliferation, migration, and invasion in bladder cancer cells.
    Tumour Biol. 2017;39:1010428317699119.
    Abstract    

    Abstract available

  8. MCPHERSON VA, Rodrigues G, Bauman G, Winquist E, et al
    Supplementary data: Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer.
    Can Urol Assoc J. 2017;11.
    Abstract    



  9. MCPHERSON VA, Rodrigues G, Bauman G, Winquist E, et al
    Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer.
    Can Urol Assoc J. 2017;11.
    Abstract    

    Abstract available

  10. SIDAWAY P
    Bladder cancer: Targeting oncofetal glycosaminoglycans.
    Nat Rev Urol. 2017 Apr 25. doi: 10.1038/nrurol.2017.
    Abstract    



  11. TERRACCIANO D, Ferro M, Terreri S, Lucarelli G, et al
    Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers.
    Transl Res. 2017 Apr 7. pii: S1931-5244(16)30227.
    Abstract    

    Abstract available

  12. LIANG LG, Kong MQ, Zhou S, Sheng YF, et al
    An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer.
    Sci Rep. 2017;7:46224.
    Abstract    

    Abstract available

  13. ZHOU Q, Song W, Xiao W
    Dioscin induces demethylation of DAPK-1 and RASSF-1alpha genes via the antioxidant capacity, resulting in apoptosis of bladder cancer T24 cells.
    EXCLI J. 2017;16:101-112.
    Abstract    

    Abstract available

  14. LIN YC, Lin JF, Wen SI, Yang SC, et al
    Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis.
    Kaohsiung J Med Sci. 2017;33:215-223.
    Abstract    

    Abstract available

  15. LI Z, Liao H, Tan Z, Mao D, et al
    Micropapillary bladder cancer: a clinico-pathological characterization and treatment analysis.
    Clin Transl Oncol. 2017 Apr 21. doi: 10.1007/s12094-017-1658.
    Abstract    

    Abstract available

  16. HOY NY, Cohn JA, Kowalik CG, Kaufman MR, et al
    Management of Voiding Dysfunction After Female Neobladder Creation.
    Curr Urol Rep. 2017;18:33.
    Abstract    

    Abstract available

  17. ZAINFELD D, Daneshmand S
    Transurethral Resection of Bladder Tumors: Improving Quality Through New Techniques and Technologies.
    Curr Urol Rep. 2017;18:34.
    Abstract    

    Abstract available

  18. AUTORINO R, Porpiglia F, Dasgupta P, Rassweiler J, et al
    Precision surgery and genitourinary cancers.
    Eur J Surg Oncol. 2017;43:893-908.
    Abstract    

    Abstract available

  19. TSUKADA H, Miyakawa H
    Henoch Schonlein Purpura Nephritis Associated with Intravesical Bacillus Calmette-Guerin (BCG) Therapy.
    Intern Med. 2017;56:541-544.
    Abstract    

    Abstract available

  20. XU A, Ahsanul Kabir Khan M, Chen F, Zhong Z, et al
    Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.
    Med Oncol. 2016;33:131.
    Abstract    

    Abstract available

  21. GAJASINGHE DG, Nazeer I, Maddumage HP, Perera C, et al
    Metachronous bladder metastases of a type 2 papillary renal cell carcinoma: a case report and review of the literature.
    World J Surg Oncol. 2016;14:219.
    Abstract    

    Abstract available

  22. LI AY, Filson CP, Hollingsworth JM, He C, et al
    Patient-Reported Convalescence and Quality of Life Recovery: A Comparison of Open and Robotic-Assisted Radical Cystectomy.
    Surg Innov. 2016;23:598-605.
    Abstract    

    Abstract available

  23. BEQUET E, Stiennon L, Lhomme A, Piette C, et al
    [Rectal prolapse revealing a tumor: The role of abdominal ultrasound].
    Arch Pediatr. 2016 Jun 2. pii: S0929-693X(16)30200.
    Abstract    

    Abstract available

  24. ZARGAR-SHOSHTARI K, Kongnyuy M, Sharma P, Fishman MN, et al
    Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.
    World J Urol. 2016;34:1567-1573.
    Abstract    

    Abstract available

  25. GOONEWARDENE SS, Persad R, Gillatt D
    Robotic radical cystectomy and enhanced recovery: a new pathway.
    World J Urol. 2016;34:1599-1600.
    Abstract    



  26. PARKER WP, Ho PL, Boorjian SA, Melquist JJ, et al
    The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy.
    World J Urol. 2016;34:1561-1566.
    Abstract    

    Abstract available

  27. SONG YP, Ma JB, Wang L, Chen EC, et al
    Efficacy and safety of late-course hypofractionated radiation therapy for muscle-invasive bladder carcinoma after bladder-conserving surgery.
    Asia Pac J Clin Oncol. 2017;13:e111-e116.
    Abstract    

    Abstract available

  28. HUANG Z, Liu H, Wang Y, Zhang C, et al
    Determining the optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
    Curr Med Res Opin. 2017 May 4:1-19. doi: 10.1080/03007995.2017.1326889.
    Abstract    

    Abstract available

  29. NAN YH, Wang Y, Sun PH, Han Y, et al
    MiR-6838 Promotes Growth and Invasion in Bladder Cancer Via Suppression of Rb.
    Oncol Res. 2017 May 4. doi: 10.3727/096504017X14928634401169.
    Abstract    

    Abstract available

  30. ZHANG Q, Huang S, Luo H, Zhao X, et al
    Eight-plex iTRAQ labeling and quantitative proteomic analysis for human bladder cancer.
    Am J Cancer Res. 2017;7:935-945.
    Abstract    

    Abstract available

  31. NAN YH, Wang J, Wang Y, Sun PH, et al
    Erratum: MiR-4295 promotes cell growth in bladder cancer by targeting BTG1.
    Am J Transl Res. 2017;9:1960.
    Abstract    

    Abstract available

  32. BIJALWAN P, Pooleri GK, Thomas A
    Comparison of sterile water irrigation versus intravesical mitomycin C in preventing recurrence of nonmuscle invasive bladder cancer after transurethral resection.
    Indian J Urol. 2017;33:144-148.
    Abstract    

    Abstract available

  33. MITASH N, Tiwari S, Agnihotri S, Mandhani A, et al
    Bladder cancer: Micro RNAs as biomolecules for prognostication and surveillance.
    Indian J Urol. 2017;33:127-133.
    Abstract    

    Abstract available

  34. PINTO IG
    Systemic therapy in bladder cancer.
    Indian J Urol. 2017;33:118-126.
    Abstract    

    Abstract available

  35. SMELSER WW, Austenfeld MA, Holzbeierlein JM, Lee EK, et al
    Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?
    Indian J Urol. 2017;33:111-117.
    Abstract    

    Abstract available

  36. KUKREJA JB, Shah JB
    Advances in surgical management of muscle invasive bladder cancer.
    Indian J Urol. 2017;33:106-110.
    Abstract    

    Abstract available

  37. KAMAT AM
    Bladder cancer: 2017 and beyond.
    Indian J Urol. 2017;33:104-105.
    Abstract    



  38. TAE BS, Kim JK, Kang M, Jeong CW, et al
    Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patients.
    Sci Rep. 2017;7:1380.
    Abstract    

    Abstract available

  39. ECKE TH, Weiss S, Stephan C, Hallmann S, et al
    UBC(R) Rapid Test for detection of carcinoma in situ for bladder cancer.
    Tumour Biol. 2017;39:1010428317701624.
    Abstract    

    Abstract available

  40. SEVERINO PF, Silva M, Carrascal M, Malagolini N, et al
    Expression of sialyl-Tn sugar antigen in bladder cancer cells affects response to Bacillus Calmette Guerin (BCG) and to oxidative damage.
    Oncotarget. 2017 Apr 17. doi: 10.18632/oncotarget.17138.
    Abstract    

    Abstract available

  41. POLETAJEW S, Radziszewski P
    Endoscopic appearance of a tumor can predict the stage of bladder cancer.
    Cent European J Urol. 2017;70:27-28.
    Abstract    



  42. SCHULZ WA, Kramer MW, Fuessel S, Stohr R, et al
    [The 6th symposium of the German Association for Bladder Cancer Research].
    Urologe A. 2017 May 2. doi: 10.1007/s00120-017-0405.
    Abstract    



  43. CHEN Y, Peng Y, Xu Z, Ge B, et al
    LncROR Promotes Bladder Cancer Cell Proliferation, Migration, and Epithelial-Mesenchymal Transition.
    Cell Physiol Biochem. 2017;41:2399-2410.
    Abstract    

    Abstract available

  44. OMAR NN, Tash RF, Shoukry Y, ElSaeed KO, et al
    Breaking the ritual metabolic cycle in order to save acetyl CoA: A potential role for mitochondrial humanin in T2 bladder cancer aggressiveness.
    J Egypt Natl Canc Inst. 2017 Apr 24. pii: S1110-0362(17)30028.
    Abstract    

    Abstract available

  45. GRZEGOLKOWSKI P, Kaczmarek K, Leminski A, Soczawa M, et al
    Assessment of the infiltrative character of bladder cancer at the time of transurethral resection: a single center study.
    Cent European J Urol. 2017;70:22-26.
    Abstract    

    Abstract available

  46. CAMPODONICO F, Di Stasi S, Lev GM, Terrone C, et al
    Intravesical chemotherapy and chemohypherthermia in non-muscle-invasive bladder cancer; an overview on drug administration technologies and pharmacokinetics.
    Curr Drug Metab. 2017 Apr 26. doi: 10.2174/1389200218666170427092421.
    Abstract    

    Abstract available

  47. YONG C, Daihui C, Bo Z
    Laparoscopic versus open radical cystectomy for patients with bladder cancer over 75-year-old: a prospective randomized controlled trial.
    Oncotarget. 2017;8:26565-26572.
    Abstract    

    Abstract available

  48. GUERRERO-RAMOS F, Lara-Isla A, Justo-Quintas J, Duarte-Ojeda JM, et al
    Adjuvant intravesical treatment for nonmuscle invasive bladder cancer: The importance of the strain and maintenance.
    Actas Urol Esp. 2017 Apr 27. pii: S0210-4806(17)30062.
    Abstract    

    Abstract available

  49. WU J, Yu C, Cai L, Lu Y, et al
    Effects of increased Kindlin-2 expression in bladder cancer stromal fibroblasts.
    Oncotarget. 2017 Apr 10. doi: 10.18632/oncotarget.17021.
    Abstract    

    Abstract available

  50. RUTHERFORD C, Costa DSJ, King MT, Smith DP, et al
    A conceptual framework for patient-reported outcomes in non-muscle invasive bladder cancer.
    Support Care Cancer. 2017 Apr 27. doi: 10.1007/s00520-017-3717.
    Abstract    

    Abstract available

  51. DROCAS AI, Tomescu PI, Mitroi G, Dragoescu PO, et al
    The cadherin switch assessment in the epithelial-mesenchymal transition of urothelial bladder carcinomas.
    Rom J Morphol Embryol. 2016;57:1037-1044.
    Abstract    

    Abstract available

  52. OBARA W, Eto M, Mimata H, Kohri K, et al
    A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.
    Ann Oncol. 2017;28:798-803.
    Abstract    

    Abstract available

  53. FINKEL ML
    Shale gas development and cancer incidence in southwest Pennsylvania.
    Public Health. 2016;141:198-206.
    Abstract    

    Abstract available

  54. DUVNJAK P, Laguna M
    Left Anterior Descending Coronary Artery and Multiple Peripheral Mycotic Aneurysms Due to Mycobacterium Bovis Following Intravesical Bacillus Calmette-Guerin Therapy: A Case Report.
    J Radiol Case Rep. 2016;10:12-27.
    Abstract    

    Abstract available

  55. ROSATI Y, Fabiani A, Taccari T, Ranaldi R, et al
    Intravesical BCG therapy as cause of miliary pulmonary tuberculosis.
    Urologia. 2016;83:49-53.
    Abstract    

    Abstract available

  56. RINALDETTI S, Wirtz RM, Worst TS, Eckstein M, et al
    FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.
    Oncotarget. 2017 Apr 24. doi: 10.18632/oncotarget.17394.
    Abstract    

    Abstract available

  57. KASAHARA R, Kawahara T, Ohtake S, Saitoh Y, et al
    A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.
    Biomed Res Int. 2017;2017:7981549.
    Abstract    

    Abstract available

  58. SANKIN A, Narasimhulu D, John P, Gartrell B, et al
    The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.
    Urol Oncol. 2017 May 8. pii: S1078-1439(17)30176.
    Abstract    

    Abstract available

  59. RAGHAVAN D
    No Bridge Over Troubled Water: Slow Progress in Bladder Cancer.
    J Oncol Pract. 2017;13:317-318.
    Abstract    



  60. WU Z, Wang S, Xue P, Wang S, et al
    Inhibitory member of the apoptosis-stimulating protein of p53 is overexpressed in bladder cancer and correlated to its progression.
    Medicine (Baltimore). 2017;96:e6640.
    Abstract    

    Abstract available

  61. YEH HL, Hsu SW, Chang YC, Chan TC, et al
    Spatial Analysis of Ambient PM2.5 Exposure and Bladder Cancer Mortality in Taiwan.
    Int J Environ Res Public Health. 2017;14.
    Abstract    

    Abstract available

  62. PAPARO SR, Fallahi P
    Bladder cancer and Th1 chemokines
    Clin Ter. 2017;168:e59-e63.
    Abstract    

    Abstract available

  63. LATOSINSKA A, Mokou M, Makridakis M, Mullen W, et al
    Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.
    Oncotarget. 2017 Apr 20. doi: 10.18632/oncotarget.17279.
    Abstract    

    Abstract available

  64. FULKERSON CM, Dhawan D, Ratliff TL, Hahn NM, et al
    Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.
    Int J Genomics. 2017;2017:6589529.
    Abstract    

    Abstract available

  65. PRADO K, Zhang KX, Pellegrini M, Chin AI, et al
    Sequencing of cancer cell subpopulations identifies micrometastases in a bladder cancer patient.
    Oncotarget. 2017 Apr 21. doi: 10.18632/oncotarget.17312.
    Abstract    

    Abstract available

  66. SALOMO K, Huebner D, Boehme MU, Herr A, et al
    Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.
    J Cancer Res Clin Oncol. 2017 May 8. doi: 10.1007/s00432-017-2433.
    Abstract    

    Abstract available

  67. OSTWAL V, Pinninti R, Ramaswamy A, Shetty N, et al
    Treatment of advanced Gall bladder cancer in the real world-can continuation chemotherapy improve outcomes?
    J Gastrointest Oncol. 2017;8:368-376.
    Abstract    

    Abstract available

  68. MOWLDS DS, Foster CE, Ichii H
    Invasive squamous cell bladder cancer of the ureterovesical junction in a renal transplant patient: a case report.
    J Surg Case Rep. 2017;2017:rjx066.
    Abstract    

    Abstract available

  69. XIA L, Taylor BL, Guzzo TJ
    Characteristics and Associated Factors of Postoperative Pulmonary Complications in Patients Undergoing Radical Cystectomy for Bladder Cancer: A National Surgical Quality Improvement Program Study.
    Clin Genitourin Cancer. 2017 Apr 13. pii: S1558-7673(17)30093.
    Abstract    

    Abstract available

  70. ZAKARIA AS, Santos F, Dragomir A, Kassouf W, et al
    Health care services utilization during the last 6 months of life among patients with bladder cancer who underwent radical cystectomy in Quebec, Canada.
    Urol Oncol. 2017 May 4. pii: S1078-1439(17)30174.
    Abstract    

    Abstract available

  71. NECCHI A, Raggi D, Giannatempo P, Sonpavde G, et al
    From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis.
    Clin Genitourin Cancer. 2017 Apr 13. pii: S1558-7673(17)30092.
    Abstract    



  72. WILLIAMS SB, Huo J, Kosarek CD, Chamie K, et al
    Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer.
    Cancer Causes Control. 2017 May 5. doi: 10.1007/s10552-017-0902.
    Abstract    

    Abstract available

  73. SRINIVASAN A, Apostolov R, Leong A, Johnson D, et al
    Atraumatic chylous ascites: an unusual presentation of bladder cancer.
    BMJ Case Rep. 2017;2017.
    Abstract    

    Abstract available

  74. GILL DM, Sonpavde G, Pal SK, Agarwal N, et al
    Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.
    Immunotherapy. 2017;9:463-466.
    Abstract    



  75. MITHQAL A, Darvishi P, Rehm P
    MIBG Localization of a Subclinical Paraganglioma of the Bladder.
    Clin Nucl Med. 2017;42:e196-e198.
    Abstract    

    Abstract available

  76. SJODAHL G, Eriksson P, Liedberg F, Hoglund M, et al
    Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.
    J Pathol. 2017;242:113-125.
    Abstract    

    Abstract available

  77. CHEN Z, Liu Q, Chen R, Liu Z, et al
    Clinical analysis of small cell carcinoma of the bladder in Chinese: nine case reports and literature reviews.
    World J Surg Oncol. 2017;15:33.
    Abstract    

    Abstract available

  78. BLANCA A, Cheng L, Montironi R, Moch H, et al
    Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice.
    Curr Drug Metab. 2017 May 18. doi: 10.2174/1389200218666170518164507.
    Abstract    

    Abstract available

  79. COHEN T, Ricchiuti D, Memo M
    Bladder cancer that metastasized to the skin: A unique presentation that signifies poor prognosis.
    Rev Urol. 2017;19:67-71.
    Abstract    

    Abstract available

  80. GAO F, Xu T, Wang X, Zhong S, et al
    CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing beta-catenin.
    J Exp Clin Cancer Res. 2017;36:70.
    Abstract    

    Abstract available

  81. HAO L, Zhao Y, Li ZG, He HG, et al
    Tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and induces apoptosis of prostate and bladder cancer cells.
    Oncol Lett. 2017;13:3638-3640.
    Abstract    

    Abstract available

  82. CHEN J, Zhang N, Wen J, Zhang Z, et al
    Silencing TAK1 alters gene expression signatures in bladder cancer cells.
    Oncol Lett. 2017;13:2975-2981.
    Abstract    

    Abstract available

  83. YAN L, Wang Y, Liang J, Liu Z, et al
    MiR-301b Promotes the Proliferation, Mobility and Epithelial-to-Mesenchymal Transition of Bladder Cancer Cells by Targeting EGR1.
    Biochem Cell Biol. 2017 May 18. doi: 10.1139/bcb-2016-0232.
    Abstract    

    Abstract available

  84. BACHIR BG, Souhami L, Mansure JJ, Cury F, et al
    Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer.
    Bladder Cancer. 2017;3:105-112.
    Abstract    

    Abstract available

  85. PAN Q, Sathe A, Black PC, Goebell PJ, et al
    CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.
    Bladder Cancer. 2017;3:79-88.
    Abstract    

    Abstract available

  86. ZHOU L, Xu L, Chen L, Fu Q, et al
    Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer.
    Oncoimmunology. 2017;6:e1293211.
    Abstract    

    Abstract available

  87. ANIL H, Karamik K, Ates M, Yuksel M, et al
    A Rare Clinical Entity in Bladder Cancer: Paraneoplastic Cerebellar Degeneration.
    Clin Genitourin Cancer. 2017 Apr 26. pii: S1558-7673(17)30110.
    Abstract    



  88. NISHIZAWA T, Yoshida S, Koga F, Tanaka H, et al
    Standardization of the apparent diffusion coefficient value of bladder cancer across different centers: Applicability in predicting aggressive pathologic phenotypes.
    Clin Imaging. 2017;44:121-126.
    Abstract    

    Abstract available

  89. LIU Q, Liu H, Cheng H, Li Y, et al
    Downregulation of long noncoding RNA TUG1 inhibits proliferation and induces apoptosis through the TUG1/miR-142/ZEB2 axis in bladder cancer cells.
    Onco Targets Ther. 2017;10:2461-2471.
    Abstract    

    Abstract available

  90. ZHANG K, Wang W, Wu K, Ding C, et al
    [Knock-down of DAB2 interacting protein (DAB2IP) promotes proliferation and inhibits apoptosis of bladder cancer cells].
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33:668-676.
    Abstract    

    Abstract available

  91. SCHMID SC, Sathe A, Guerth F, Seitz AK, et al
    Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin.
    Urol Oncol. 2017 May 10. pii: S1078-1439(17)30187.
    Abstract    

    Abstract available

  92. IBANEZ MUNOZ D, Quintana Martinez I, Fernandez Militino A, Sanchez Zalabardo D, et al
    Virtual cystoscopy, computed tomography urography and optical cystoscopy for the detection and follow-up for bladder cancer.
    Radiologia. 2017 May 10. pii: S0033-8338(17)30054.
    Abstract    

    Abstract available

  93. AVELLINI C, Licini C, Lazzarini R, Gesuita R, et al
    The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer.
    Oncotarget. 2017 Apr 25. doi: 10.18632/oncotarget.17407.
    Abstract    

    Abstract available

  94. NORO D, Hatakeyama S, Yoneyama T, Hashimoto Y, et al
    Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy.
    Med Oncol. 2017;34:117.
    Abstract    

    Abstract available

  95. SROUGI V, Gallucci FP, Mattedi RL, Srougi M, et al
    Carcinosarcoma of the bladder following local schistosomiasis infection.
    BMJ Case Rep. 2017;2017.
    Abstract    

    Abstract available

  96. ERBAY G, Akyol F, Karabakan M, Celebi B, et al
    Effect of obturator nerve block during transurethral resection of lateral bladder wall tumors on the presence of detrusor muscle in tumor specimens and recurrence of the disease.
    Kaohsiung J Med Sci. 2017;33:86-90.
    Abstract    

    Abstract available

  97. TAO T, He C, Deng J, Huang Y, et al
    A novel synthetic derivative of quercetin, 8-trifluoromethyl- 3,5,7,3',4'-O-pentamethyl-quercetin, inhibits bladder cancer growth by targeting the AMPK/mTOR signaling pathway.
    Oncotarget. 2017 May 11. doi: 10.18632/oncotarget.17799.
    Abstract    

    Abstract available

  98. YIN H, Yang X, Gu W, Liu Y, et al
    HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation.
    Oncotarget. 2017 May 11. doi: 10.18632/oncotarget.17796.
    Abstract    

    Abstract available

  99. WANG YN, Wang FD, Zhu L
    [Ileo-vaginal fistula caused by bladder cancer recurrence after posterior colporrhaphy: a case report].
    Zhonghua Fu Chan Ke Za Zhi. 2017;52:343.
    Abstract    



  100. MIKHAIL AS, Negussie AH, Pritchard WF, Haemmerich D, et al
    Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer.
    Int J Hyperthermia. 2017 May 10:1-8. doi: 10.1080/02656736.2017.1315459.
    Abstract    

    Abstract available

  101. WARD DG, Bryan RT
    Liquid biopsies for bladder cancer.
    Transl Androl Urol. 2017;6:331-335.
    Abstract    

    Abstract available

  102. EL SAYED I, Elkhwsky F, La Vecchia C, Alicandro G, et al
    The frequency of bladder cancer in Alexandria, Egypt, over the last two decades.
    Eur J Cancer Prev. 2017 May 19. doi: 10.1097/CEJ.0000000000000368.
    Abstract    



  103. KUTWIN P, Konecki T, Cichocki M, Falkowski P, et al
    Photodynamic Diagnosis and Narrow-Band Imaging in the Management of Bladder Cancer: A Review.
    Photomed Laser Surg. 2017 May 22. doi: 10.1089/pho.2016.4217.
    Abstract    

    Abstract available

  104. YURUK E, Tuken M, Colakerol A, Serefoglu EC, et al
    The awareness of patients with non - muscle invasive bladder cancer regarding the importance of smoking cessation and their access to smoking cessation programs.
    Int Braz J Urol. 2017;43.
    Abstract    

    Abstract available

  105. MALMSTROM PU, Agrawal S, Blackberg M, Bostrom PJ, et al
    Non-muscle-invasive bladder cancer: a vision for the future.
    Scand J Urol. 2017 Feb 7:1-8. doi: 10.1080/21681805.2017.1283359.
    Abstract    

    Abstract available

  106. JOHN BA, Said N
    Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.
    Oncotarget. 2017 May 9. doi: 10.18632/oncotarget.17714.
    Abstract    

    Abstract available

  107. KOLLBERG P, Almquist H, Blackberg M, Cwikiel M, et al
    [18F]Fluorodeoxyglucose-positron emission tomography/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer.
    Scand J Urol. 2017 May 22:1-6. doi: 10.1080/21681805.2017.1321579.
    Abstract    

    Abstract available

  108. GOPALAKRISHNA A, Longo TA, Fantony JJ, Harrison MR, et al
    Physical activity patterns and associations with health-related quality of life in bladder cancer survivors.
    Urol Oncol. 2017 May 17. pii: S1078-1439(17)30188.
    Abstract    

    Abstract available

  109. PARIDA GK, Tripathy S, Roy SG, Singhal A, et al
    Incidentally Detected Penile Metastases in a Patient of Carcinoma Urinary Bladder on Follow-up FDG PET/CT.
    Clin Nucl Med. 2017 Mar 10. doi: 10.1097/RLU.0000000000001607.
    Abstract    

    Abstract available

  110. RICARDO HUPPES R, Crivellenti LZ, Barboza De Nardi A, Roque Lima B, et al
    Radical Cystectomy and Cutaneous Ureterostomy in 4 Dogs with Trigonal Transitional Cell Carcinoma: Description of Technique and Case Series.
    Vet Surg. 2017;46:111-119.
    Abstract    

    Abstract available


  111. This Month in AJP.
    Am J Pathol. 2017;187:1.
    Abstract    

    Abstract available

  112. MAKINO K, Nakagawa T, Kanatani A, Kawai T, et al
    Biphasic decline in renal function after radical cystectomy with urinary diversion.
    Int J Clin Oncol. 2017;22:359-365.
    Abstract    

    Abstract available

  113. NGUYEN HT, Shah ZK, Mortazavi A, Pohar KS, et al
    Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.
    Eur Radiol. 2017;27:2146-2152.
    Abstract    

    Abstract available

  114. SMEDINGA H, Steyerberg EW, Beukers W, van Klaveren D, et al
    Prediction of Multiple Recurrent Events: A Comparison of Extended Cox Models in Bladder Cancer.
    Am J Epidemiol. 2017 May 19. doi: 10.1093.
    Abstract    

    Abstract available

  115. MANIG L, Kasmann L, Janssen S, Schild SE, et al
    Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer.
    Anticancer Res. 2017;37:2693-2696.
    Abstract    

    Abstract available

  116. KHANAL A, Budhathoki N, Singh VP, Shah BK, et al
    Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
    Anticancer Res. 2017;37:2033-2036.
    Abstract    

    Abstract available

  117. MATARAZA JM, Gotwals P
    Recent advances in immuno-oncology and its application to urological cancers.
    BJU Int. 2016;118:506-14.
    Abstract    

    Abstract available

  118. LONGO N, Imbimbo C, Fusco F, Ficarra V, et al
    Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy.
    BJU Int. 2016;118:521-6.
    Abstract    

    Abstract available

  119. ZHANG C, Ma X, Du J, Yao Z, et al
    MicroRNA-30a as a prognostic factor in urothelial carcinoma of bladder inhibits cellular malignancy by antagonising Notch1.
    BJU Int. 2016;118:578-89.
    Abstract    

    Abstract available

  120. MEYER CP, Rios Diaz AJ, Dalela D, Hanske J, et al
    Wound dehiscence in a sample of 1 776 cystectomies: identification of predictors and implications for outcomes.
    BJU Int. 2016;117.
    Abstract    

    Abstract available

  121. NGO B, Papa N, Perera M, Bolton D, et al
    Bladder cancer diagnosis during haematuria investigation - implications for practice guidelines.
    BJU Int. 2017;119 Suppl 5:53-54.
    Abstract    



  122. HAYNE D
    Bladder cancer - Old lessons yet to be learned.
    BJU Int. 2017;119 Suppl 5:7.
    Abstract    



  123. NGO B, Perera M, Papa N, Bolton D, et al
    Factors affecting the timeliness and adequacy of haematuria assessment in bladder cancer: a systematic review.
    BJU Int. 2017;119 Suppl 5:10-18.
    Abstract    

    Abstract available

  124. LAWRENTSCHUK N
    Bladder cancer- time for a higher profile in our region.
    BJU Int. 2017;119 Suppl 5:5.
    Abstract    



  125. GOLOMBOS DM, O'Malley P, Lewicki P, Stone BV, et al
    Robot-assisted partial cystectomy: perioperative outcomes and early oncological efficacy.
    BJU Int. 2017;119:128-134.
    Abstract    

    Abstract available

  126. VAN KAMPEN JGM, van Hooij O, Jansen CF, Smit FP, et al
    miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2.
    Cancer Res. 2017;77:2008-2017.
    Abstract    

    Abstract available

  127. GALSKY MD, Sfakianos JP, Ferket BS
    Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30292.
    Abstract    



  128. SOUKUP V, Capoun O, Cohen D, Hernandez V, et al
    Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel
    Eur Urol. 2017 Apr 27. pii: S0302-2838(17)30323.
    Abstract    

    Abstract available

  129. KULKARNI GS, Klaassen Z
    Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details?
    Eur Urol. 2017 May 5. pii: S0302-2838(17)30338.
    Abstract    



  130. BABJUK M
    Bladder Cancer in the Elderly.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30326.
    Abstract    



  131. FONTEYNE V, Ost P, Bellmunt J, Droz JP, et al
    Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30230.
    Abstract    

    Abstract available

  132. SOAVE A, Riethdorf S, Dahlem R, von Amsberg G, et al
    A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy.
    Int J Cancer. 2017;140:381-389.
    Abstract    

    Abstract available

  133. FENG C, Sun P, Hu J, Feng H, et al
    miRNA-556-3p promotes human bladder cancer proliferation, migration and invasion by negatively regulating DAB2IP expression.
    Int J Oncol. 2017 Apr 20. doi: 10.3892/ijo.2017.3969.
    Abstract    

    Abstract available

  134. KIM WT, Seo SP, Byun YJ, Kang HW, et al
    Garlic extract in bladder cancer prevention: Evidence from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis.
    Int J Oncol. 2017 May 11. doi: 10.3892/ijo.2017.3993.
    Abstract    

    Abstract available

  135. XIONG Y, Huang F, Li X, Chen Z, et al
    CCL21/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK/ERK1/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer.
    Int J Oncol. 2017 May 17. doi: 10.3892/ijo.2017.4003.
    Abstract    

    Abstract available

  136. CHEN M, Lv JM, Ye JQ, Cui XG, et al
    Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cells.
    Int J Oncol. 2017 May 16. doi: 10.3892/ijo.2017.3997.
    Abstract    

    Abstract available

  137. RAVVAZ K, Walz ME, Weissert JA, Downs TM, et al
    Predicting non-muscle invasive bladder cancer recurrence and progression in a US population.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54785-0. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  138. CHANG SS, Bochner BH, Chou R, Dreicer R, et al
    Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
    J Urol. 2017 Apr 26. pii: S0022-5347(17)57836-2. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  139. LAGUNA MP
    Re: Oncologic Outcomes of Kidney-Sparing Surgery versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-Muscle Invasive Bladder Cancer Guidelines Panel.
    J Urol. 2017;197:1437-1438.
    Abstract    



  140. HAN AL, Veeneman BA, El-Sawy L, Day KC, et al
    Fibulin-3 promotes muscle-invasive bladder cancer.
    Oncogene. 2017 May 15. doi: 10.1038/onc.2017.
    Abstract    

    Abstract available

  141. YUAN SY, Shiau MY, Ou YC, Huang YC, et al
    Miconazole induces apoptosis via the death receptor 5-dependent and mitochondrial-mediated pathways in human bladder cancer cells.
    Oncol Rep. 2017 Apr 27. doi: 10.3892/or.2017.5608.
    Abstract    

    Abstract available

  142. WU D, Niu X, Tao J, Li P, et al
    MicroRNA-379-5p plays a tumor-suppressive role in human bladder cancer growth and metastasis by directly targeting MDM2.
    Oncol Rep. 2017 Apr 27. doi: 10.3892/or.2017.5607.
    Abstract    

    Abstract available

  143. LAVOIE JM, Bidnur S, Black PC, Eigl BJ, et al
    Expanding Immunotherapy Options for Bladder Cancer.
    Urology. 2017 Apr 25. pii: S0090-4295(17)30344.
    Abstract    



  144. SORIA F, Moschini M, Wirth GJ, Gust KM, et al
    Characterization of Late Recurrence after Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients.
    Urology. 2017 May 12. pii: S0090-4295(17)30487.
    Abstract    

    Abstract available

  145. KAO YT, Wu CH, Wu SY, Lan SH, et al
    Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells.
    BMC Cancer. 2017;17:277.
    Abstract    

    Abstract available

  146. FONTEYNE V, Dirix P, Junius S, Rammant E, et al
    Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial.
    BMC Cancer. 2017;17:308.
    Abstract    

    Abstract available

  147. TEYSSONNEAU D, Daste A, Dousset V, Hoepffner JL, et al
    Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
    BMC Cancer. 2017;17:323.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;